COVID Vaccines

Bharat Biotech today announced COVAXIN Latest Peer Review published in the Lancet Infectious Disease Journal . The company stated, the peer review of BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study. The study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal....

A COVAXIN booster dose has protective efficacy against the Delta variant and the Omicron sub-variants BA.1.1 and BA.2, according to a recent published study by the Indian Council of Medical Research (ICMR), the National Institute of Virology (NIV), and Bharat Biotech. The neutralising antibody response against variants of concern, such as Delta and Omicron, was found to be enhanced by the booster dosage of Covaxin....

CEPI will provide funding of up to US$19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium comprising Bharat Biotech International Ltd (BBIL), India, the University of Sydney, Australia and ExcellGene SA, Switzerland. Bharat Biotech, University of Sydney and ExcellGene consortium is the latest award that CEPI announced today under its $200 mn programme to advance the development...

Hyderabad: India has approved COVAXIN for children 6 to 12 years of age today. Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, announced that BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate, has received emergency use approval in children 6-12 years of age. Covaxin for children facts to know COVAXIN was earlier approved for children 12-18 years of age.Whole-Virion...

Covaxin Commercialisation rights has been secured by Ocugen Inc. Ocugen and Bharat Biotech has entered into amended agreement to expand the US firm’s Co-development, Supply and Commercialization, and the exclusive territory of commercialisation of Covaxin, a Covid-19 vaccine of the Indian vaccine maker, to Mexico. COVAXIN™️ can be an ideal vaccination option for Mexico at this stage of the pandemic. As a whole virion, inactivated...

COVAXIN Price is now Rs. 225/- per dose at Private Hospitals. We welcome the decision to make available precautionary dose for all adults. In consultation with the Central Government, we have decided to revise the price of #COVAXIN from Rs 1200 to Rs 225 per dose, for private hospitals, Suchitra Ella the Joint Managing Director of Bharat Biotech Tweeted. Check out the New Covaxin Price...

Vaccination drives at most private hospitals were suspended due to the low turnout, as the State government in States such as Tamil Nadu has started administering Covaxin and Covishield free of cost. According to data from the Directorate of Public Health, just 10,000 Sputnik V doses have been administered in private hospitals across the state of Tamil Nadu thus far. In the meantime, the state...

COVAXIN maker Bharat Biotech announced today that U.S. Food and Drug Administration (FDA) has lifted its clinical hold to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN® outside the United States. COVAXIN® has already been granted Emergency Use Listing (EUL) in several countries as on January 31 according to the WHO. COVAXIN was granted EUL by the national regulator, Drugs Controller General of India...

India has accorded Emergency Use authorization for Sputnik Light today. The drug regulator DCGI (Drugs Controller General of India) has granted emergency use permission to Single-dose Sputnik Light COVID-19 vaccine in India, Union health minister Dr Mansukh Mandaviya said today. He said the emergency use approval of the single-dose vaccine will give a boost to India's fight against Covid-19. “This is the 9th #COVID19...

Inoculating entire populations with a intra nasal vaccine would be faster in the thick of a covid19 viral infection surge than injections, which require skill and time to administer. A nasal vaccine is likely to be more agreeable to many (including children) than painful injections, and would not only offset shortages of needles, syringes and other materials but also will minimize e-waster. Scientist, Founder &...